143 related articles for article (PubMed ID: 22101219)
21. Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial.
Peters-Lawrence MH; Bell MC; Hsu LL; Osunkwo I; Seaman P; Blackwood M; Guillaume E; Bellevue R; Krishnamurti L; Smith WR; Dampier CD; Minniti CP;
Contemp Clin Trials; 2012 Mar; 33(2):291-7. PubMed ID: 22155024
[TBL] [Abstract][Full Text] [Related]
22. Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.
Berk S; Greco BL; Biglan K; Kopil CM; Holloway RG; Meunier C; Simuni T
J Parkinsons Dis; 2017; 7(4):685-693. PubMed ID: 29103052
[TBL] [Abstract][Full Text] [Related]
23. Practical aspects of clinical trials on chemoprevention of prostate cancer.
van der Meijden AP
Eur Urol; 1999; 35(5-6):515-8. PubMed ID: 10325517
[TBL] [Abstract][Full Text] [Related]
24. Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.
Gohagan JK; Broski K; Gren LH; Fouad MN; Higgins D; Lappe K; Ogden S; Shambaugh V; Pinsky PF; O'Brien B; Yurgalevich S; Riley T; Wright P; Prorok PC
Rev Recent Clin Trials; 2015; 10(3):187-93. PubMed ID: 26435288
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
26. Patient-centered recruitment and retention for a randomized controlled study.
Chhatre S; Jefferson A; Cook R; Meeker CR; Kim JH; Hartz KM; Wong YN; Caruso A; Newman DK; Morales KH; Jayadevappa R
Trials; 2018 Mar; 19(1):205. PubMed ID: 29587805
[TBL] [Abstract][Full Text] [Related]
27. Successful subject recruitment for a prostate cancer behavioral intervention trial.
Heiney SP; Arp Adams S; Drake BF; Bryant LH; Bridges L; Hebert JR
Clin Trials; 2010 Aug; 7(4):411-7. PubMed ID: 20571136
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer chemoprevention: current status and future prospects.
Gupta S
Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
[TBL] [Abstract][Full Text] [Related]
29. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
Lara PN; Higdon R; Lim N; Kwan K; Tanaka M; Lau DH; Wun T; Welborn J; Meyers FJ; Christensen S; O'Donnell R; Richman C; Scudder SA; Tuscano J; Gandara DR; Lam KS
J Clin Oncol; 2001 Mar; 19(6):1728-33. PubMed ID: 11251003
[TBL] [Abstract][Full Text] [Related]
30. Implementation of the Prostate Cancer Prevention Trial (PCPT).
Goodman PJ; Tangen CM; Crowley JJ; Carlin SM; Ryan A; Coltman CA; Ford LG; Thompson IM
Control Clin Trials; 2004 Apr; 25(2):203-22. PubMed ID: 15020037
[TBL] [Abstract][Full Text] [Related]
31. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.
Goodman PJ; Tangen CM; Darke AK; Arnold KB; Hartline J; Yee M; Anderson K; Caban-Holt A; Christen WG; Cassano PA; Lance P; Klein EA; Crowley JJ; Minasian LM; Meyskens FL
Trials; 2016 Aug; 17():400. PubMed ID: 27519183
[TBL] [Abstract][Full Text] [Related]
32. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.
Unger JM; Barlow WE; Tangen CM; Ramsey SD; Thompson IM; Klein EA; LeBlanc M; Blanke CD; Goodman PJ; Minasian LM; Nghiem VT; Hershman DL
Cancer Epidemiol; 2018 Aug; 55():117-122. PubMed ID: 29936140
[TBL] [Abstract][Full Text] [Related]
33. Responding to a significant recruitment challenge within three nationwide psychoeducational trials for cancer patients.
Stanton AL; Morra ME; Diefenbach MA; Miller SM; Slevin Perocchia R; Raich PC; Fleisher L; Wen KY; Tran ZV; Mohamed NE; George R; Bright MA; Marcus AC
J Cancer Surviv; 2013 Sep; 7(3):392-403. PubMed ID: 23595235
[TBL] [Abstract][Full Text] [Related]
34. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of prostate cancer: an updated view.
Klein EA; Thompson IM
World J Urol; 2012 Apr; 30(2):189-94. PubMed ID: 22238120
[TBL] [Abstract][Full Text] [Related]
36. Phase III prostate cancer chemoprevention trials.
Parnes HL; Brawley OW; Minasian LM; Ford LG
Recent Results Cancer Res; 2014; 202():73-7. PubMed ID: 24531780
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.
Kattan MW; Earnshaw SR; McDade CL; Black LK; Andriole GL
Appl Health Econ Health Policy; 2011 Sep; 9(5):305-15. PubMed ID: 21875161
[TBL] [Abstract][Full Text] [Related]
38. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
Simpson NK; Johnson CC; Ogden SL; Gamito E; Trocky N; McGuire C; Martin J; Barrow S; Lamerato L; Flickinger LM; Broski KG; Engelhard D; Hilke C; Bonk J; Gahagan B; Gren LH; Childs J; Lappe K; Fouad M; Thompson J; Sullivan D;
Control Clin Trials; 2000 Dec; 21(6 Suppl):356S-378S. PubMed ID: 11189688
[TBL] [Abstract][Full Text] [Related]
39. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
Alberts SR; Novotny PJ; Sloan JA; Danella J; Bostwick DG; Sebo TJ; Blute ML; Fitch TR; Levitt R; Lieberman R; Loprinzi CL
Am J Ther; 2006; 13(4):291-7. PubMed ID: 16858161
[TBL] [Abstract][Full Text] [Related]
40. Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention.
Shirai T
Pathol Int; 2008 Jan; 58(1):1-16. PubMed ID: 18067635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
